Article
Oncology
Citadel J. Cabasag, Melina Arnold, Marion Pineros, Eileen Morgan, James Brierley, Jim Hofferkamp, Sean Kehoe, John Butler, Oliver Bucher, Freddie Bray, Isabelle Soerjomataram, D. Maxwell Parkin
Summary: Cancer stage at diagnosis is crucial for managing individual patients and evaluating health care system effectiveness. International comparison of cancer survival by stage is challenging due to lack of standardized recording and variation in stage completeness across countries. Development of stage conversion algorithms and improvement of staging data completeness are recommended for valid international comparison.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Oncology
Hollie A. Clements, Tim J. Underwood, Russell D. Petty
Summary: Adenocarcinoma of the oesophagus and gastro-oesophageal junction is a major cause of cancer death in the Western World, with increasing incidence. The overall survival of patients on a potentially curative treatment pathway has significantly improved by adding perioperative oncological therapies to surgery. However, patients often have poor response to oncological treatment or struggle to complete their treatment after surgery.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Samuel L. Cytryn, Ryan H. Moy, Darren Cowzer, Ronak H. Shah, Joanne F. Chou, Smita S. Joshi, Geoffrey Y. Ku, Steven B. Maron, Avni Desai, Jessica Yang, Ryan Sugarman, Devika Rao, Zoe Goldberg, Carmelina Charalambous, Maria Lapshina, Ariel Antoine, Fiona Socolow, Nikhil Trivedi, Marinela Capanu, Hans Gerdes, Mark A. Schattner, Marc Simmons, Mario E. Lacouture, Viktoriya Paroder, Laura H. Tang, Jinru Shia, David H. Ilson, David B. Solit, Michael F. Berger, Yelena Y. Janjigian
Summary: This study evaluated the safety and activity of the combination of regorafenib with nivolumab and chemotherapy in the first-line treatment of advanced oesophagogastric adenocarcinoma. The results showed a high survival rate and manageable adverse events.
Article
Oncology
Ji Hyun Kim, Hyeong In Ha, Min Hae Kim, Mi Ra Han, Sang-Yoon Park, Myong Cheol Lim
Summary: By modifying institutional procedures for intraperitoneal chemotherapy (IP), including insertion of an IP port in a neutral abdominal position, daily irrigation of the peritoneal cavity with warmed dextrose fluid, and intravenous infusion of cisplatin after left colonic surgery, the completion rate of IP chemotherapy in patients with ovarian cancer was improved, even after left colonic surgery. An average of 63.0% of patients completed all six cycles of IP chemotherapy, with the most common toxicities being gastrointestinal issues and neutropenia. Further studies are needed to confirm the impact of these modifications on survival outcomes.
Article
Oncology
Xiaotian Zhang, Han Liang, Ziyu Li, Yingwei Xue, Yanong Wang, Zhiwei Zhou, Jiren Yu, Zhaode Bu, Lin Chen, Yian Du, Xinbao Wang, Aiwen Wu, Guoli Li, Xiangqian Su, Gang Xiao, Ming Cui, Dan Wu, Li Chen, Xiaojiang Wu, Yanbing Zhou, Lianhai Zhang, Chengxue Dang, Yulong He, Zhongtao Zhang, Yihong Sun, Yong Li, Huanqiu Chen, Yuxian Bai, Changsong Qi, Peiwu Yu, Guanbao Zhu, Jian Suo, Baoqing Jia, Leping Li, Changming Huang, Fei Li, Yingjiang Ye, Huimian Xu, Xin Wang, Yannan Yuan, E. Jian-Yu, Xiangji Ying, Chen Yao, Lin Shen, Jiafu Ji
Summary: The study found that perioperative SOX treatment was more effective than adjuvant CapOx treatment in patients with locally advanced gastric cancer; adjuvant SOX treatment was non-inferior to adjuvant CapOx treatment in these patients, with similar safety profiles.
Article
Oncology
Yaniv Berger, Mihai Giurcanu, Charles C. Vining, Darryl Schuitevoerder, Mitchell C. Posner, Kevin K. Roggin, Blase N. Polite, Chih-Yi Liao, Oliver S. Eng, Daniel V. T. Catenacci, Kiran K. Turaga
Summary: The study found that in patients receiving systemic chemotherapy, cytoreductive surgery (CRS) may be associated with longer overall survival compared to no surgery. Patients undergoing CRS were younger, had a lower proportion of disease involving multiple sites, and were more likely to have clinically occult disease.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
Luca Saragoni, Leonardo Solaini, Daniele Marrelli, Maria Raffaella Ambrosio, Maria Bencivenga, Anna Tomezzoli, Carlo Milandri, Valentina Terrinazzi, Gian Luca Baiocchi, Carla Baronchelli, Flavia Foca, Giorgio Ercolani, Paolo Morgagni
Summary: This study validates a nodal regression system for gastric cancer and demonstrates its significant correlation with prognosis, as well as its impact on clinico-pathological characteristics and prognosis.
INTERNATIONAL JOURNAL OF SURGERY
(2021)
Review
Biotechnology & Applied Microbiology
Suhana Ahmad, Lidawani Lambuk, Naveed Ahmed, Ali Mussa, Vincent Tee, Ros Akmal Mohd Idris, Nur Fazimah Sahran, Yean Yean Chan, Rosline Hassan, Yeong Yeh Lee, Rohimah Mohamud
Summary: Nab-paclitaxel demonstrates good efficacy and safety in the treatment of metastatic gastric cancer, providing better disease response and longer survival.
Article
Oncology
A. I. Damanakis, F. Gebauer, A. Stapper, H. A. Schloesser, M. Ghadimi, T. Schmidt, L. M. Schiffmann, H. Fuchs, T. Zander, A. Quaas, C. J. Bruns, W. Schroeder
Summary: By analyzing 715 patients with oesophageal squamous cell carcinoma (SCC) or adenocarcinoma (AC) who received neoadjuvant treatment, it was found that combining histopathologic regression and nodal status can improve the prediction of survival after treatment.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Jianping Guo, Zhizhong Xiong, Shi Yin, Yue'e Wen, Longyang Jin, Caiqin Wang, Huaxian Chen, Dandong Luo, Zijian Deng, Dayin Huang, Xianzhe Li, Biying Yi, Chaobin Mao, Lei Lian
Summary: This study identified 75 years old as the optimal age cutoff for defining EGC, and found that EGC patients had significantly worse overall survival and cancer-specific survival compared to non-EGC group. Adjuvant chemotherapy was proved to be unbeneficial for stage II EGC patients.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Genetics & Heredity
Jingxuan Xu, Jian Wen, Shuangquan Li, Xian Shen, Tao You, Yingpeng Huang, Chongyong Xu, Yaping Zhao
Summary: Recent findings have demonstrated that a nine-miRNA signature (ImmiRSig) in gastric cancer patients can effectively stratify patients into high- and low-risk groups with significantly different survival rates. The ImmiRSig may serve as an independent prognostic factor and have significant clinical implications for guiding personalized treatment and improving outcome predictions in gastric cancer patients. Additionally, ImmiRSig may potentially predict the clinical efficacy of chemotherapy based on its associations with chemotherapeutic agents.
FRONTIERS IN GENETICS
(2021)
Article
Medicine, Research & Experimental
Pengfei Su, Lin Jiang, Yingjing Zhang, Tian Yu, Hongyun Huang, Moxi Chen, Can Cao, Weiming Kang, Yuqin Liu, Jianchun Yu
Summary: This study compared the efficacy of perioperative chemotherapy (PEC) and adjuvant chemotherapy (AC) in resectable locally advanced gastric cancer (LAGC) patients. The results showed that PEC led to a higher R0 resection rate and tumor downstage, without increasing postoperative complications or grade 3/4 adverse events related to AC. PEC was independently associated with better overall survival (OS) and disease-free survival (DFS) in resectable LAGC.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2023)
Article
Oncology
Yang Liu, Yoshifumi Baba, Takatsugu Ishimoto, Hiroyasu Tsutsuki, Tianli Zhang, Daichi Nomoto, Kazuo Okadome, Kensuke Yamamura, Kazuto Harada, Kojiro Eto, Yukiharu Hiyoshi, Masaaki Iwatsuki, Yohei Nagai, Shiro Iwagami, Yuji Miyamoto, Naoya Yoshida, Yoshihiro Komohara, Masaki Ohmuraya, Xiaoming Wang, Jaffer A. Ajani, Tomohiro Sawa, Hideo Baba
Summary: F. nucleatum infection was found to reduce chemotherapeutic response in ESCC patients, by modulating autophagy to induce resistance against 5-FU, CDDP, and Docetaxel. Targeting F. nucleatum during chemotherapy may lead to improved therapeutic outcomes for ESCC patients.
BRITISH JOURNAL OF CANCER
(2021)
Article
Surgery
S. K. Kamarajah, A. W. Phillips, L. Ferri, W. L. Hofstetter, S. R. Markar
Summary: For patients with esophageal adenocarcinoma (OAC), although neoadjuvant chemoradiotherapy (nCRT) offers pathological benefits, there is no prognostic advantage compared to chemotherapy (nCT); on the contrary, for patients with squamous cell carcinoma (OSCC), nCRT provides both pathological and prognostic benefits.
BRITISH JOURNAL OF SURGERY
(2021)
Article
Oncology
Daisuke Fujimoto, Keizo Taniguchi, Junpei Takashima, Hirotoshi Kobayashi
Summary: The study aimed to evaluate the relationship between postoperative early body weight loss (EWL) and recurrence in patients with stage III gastric cancer who received postoperative adjuvant chemotherapy. It was found that EWL was closely correlated to compliance with adjuvant chemotherapy and was an independent predictor of relapse-free survival (RFS) in these patients.
Article
Oncology
David K. Lau, Maria Aresu, Timothy Planche, Amina Tran, Retchel Lazaro-Alcausi, Julie Duncan, Shannon Kidd, Susan Cromarty, Ruwaida Begum, Isma Rana, Su Li, Ali Abdulnabi Mohamed, Irene Monahan, David J. Clark, Nicholas Eckersley, Henry M. Staines, Elisabetta Groppelli, Sanjeev Krishna, Martin Mayora-Neto, Nigel Temperton, Charlotte Fribbens, David Watkins, Naureen Starling, Ian Chau, David Cunningham, Sheela Rao
Summary: The study evaluated the prevalence of neutralizing antibodies in 152 gastrointestinal cancer patients receiving chemotherapy after SARS-CoV-2 vaccination, finding that despite the immunosuppressive effects of chemotherapy, two doses of vaccines can still induce a protective immune response in patients undergoing treatment.
Article
Gastroenterology & Hepatology
Paula Ghaneh, Daniel Palmer, Silvia Cicconi, Richard Jackson, Christopher Michael Halloran, Charlotte Rawcliffe, Rajaram Sripadam, Somnath Mukherjee, Zahir Soonawalla, Jonathan Wadsley, Ahmed Al-Mukhtar, Euan Dickson, Janet Graham, Long Jiao, Harpreet S. Wasan, Iain S. Tait, Andreas Prachalias, Paul Ross, Juan W. Valle, Derek A. O'Reilly, Bilal Al-Sarireh, Sarah Gwynne, Irfan Ahmed, Kate Connolly, Kein-Long Yim, David Cunningham, Thomas Armstrong, Caroline Archer, Keith Roberts, Yuk Ting Ma, Christoph Springfeld, Christine Tjaden, Thilo Hackert, Markus W. Buchler, John P. Neoptolemos, European Study Group for Pancreatic Cancer European Study Grp Pancreat Canc
Summary: The study compared the feasibility and efficacy of three different types of short-course neoadjuvant therapy with immediate surgery. The findings showed that neoadjuvant chemotherapy significantly prolonged survival, with gemcitabine plus capecitabine or FOLFIRINOX regimen demonstrating the best results.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Medicine, General & Internal
Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M. Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, Luis Fayad, John Radford, Sarah Bailly, Fritz Offner, David Morgan, Javier Munoz, Jerry Ping, Edith Szafer-Glusman, Karl Eckert, Jutta K. Neuenburg, Andre Goy
Summary: This study evaluated the efficacy and safety of the combination of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory DLBCL ineligible for stem cell transplantation. The results showed that the combination therapy demonstrated durable antitumor activity in DLBCL patients.
Article
Oncology
Susanna Slater, Annette Bryant, Hsiang-Chi Chen, Ruwaida Begum, Isma Rana, Maria Aresu, Clare Peckitt, Oleg Zhitkov, Retchel Lazaro-Alcausi, Victoria Borja, Rachel Powell, David Lowery, Michael Hubank, Thereasa Rich, Gayathri Anandappa, Ian Chau, Naureen Starling, David Cunningham
Summary: This study aims to determine whether a de-escalation strategy using ctDNA to guide adjuvant chemotherapy is as effective as standard of care chemotherapy in patients with resected colorectal cancer. The primary endpoint is the difference in disease-free survival at 3 years between the trial arms. The study has the potential to reduce unnecessary chemotherapy and associated toxicity.
Article
Oncology
David K. Lau, Caroline Fong, Faten Arouri, Lillian Cortez, Hannah Katifi, Reyes Gonzalez-Exposito, Muhammad Bilal Razzaq, Su Li, Aislinn Macklin-Doherty, Monica Arenas Hernandez, Michael Hubank, Charlotte Fribbens, David Watkins, Sheela Rao, Ian Chau, David Cunningham, Naureen Starling
Summary: A retrospective study was conducted in a high volume cancer center in London to evaluate the impact of implementing DPYD variant testing for gastrointestinal cancer patients. The results showed that DPYD genotype testing prior to fluoropyrimidine chemotherapy ensured patient safety and the incidence of adverse events was similar to wild-type carriers.
Article
Oncology
Avani Athauda, Matthew Nankivell, Rupert Langer, Susan Pritchard, Ruth E. Langley, Katharina von Loga, Naureen Starling, Ian Chau, David Cunningham, Heike I. Grabsch
Summary: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Eric Van Cutsem, Maria di Bartolomeo, Elizabeth Smyth, Ian Chau, Haeseong Park, Salvatore Siena, Sara Lonardi, Zev A. Wainberg, Jaffer Ajani, Joseph Chao, Yelena Janjigian, Amy Qin, Jasmeet Singh, Ferdous Barlaskar, Yoshinori Kawaguchi, Geoffrey Ku
Summary: The DESTINY-Gastric02 trial is a phase 2 study evaluating the efficacy of trastuzumab deruxtecan in HER2-positive advanced gastric and gastro-oesophageal junction cancer. The results demonstrate clinically meaningful response rates, supporting its use as second-line therapy for these patients.
Article
Microbiology
James L. Alexander, Joram M. Posma, Alasdair Scott, Liam Poynter, Sam E. Mason, M. Luisa Doria, Lili Herendi, Lauren Roberts, Julie A. K. McDonald, Simon Cameron, David J. Hughes, Vaclav Liska, Simona Susova, Pavel Soucek, Verena Horneffer-van Der Sluis, Maria Gomez-Romero, Matthew R. Lewis, Lesley Hoyles, Andrew Woolston, David Cunningham, Ara Darzi, Marco Gerlinger, Robert Goldin, Zoltan Takats, Julian R. Marchesi, Julian Teare, James Kinross
Summary: This study investigates the association between gut microbiota, metabolome, and colorectal cancer (CRC). The authors identify specific microbiota clusters, such as cluster 7 containing Fusobacterium nucleatum and Granulicatella adiacens, that are strongly associated with CRC and can predict favorable disease-free survival. They also find that cluster 1 containing Faecalibacterium prausnitzii and Ruminococcus gnavus is negatively associated with cancer and predicts worse disease-free survival. In addition, certain metabolic clusters show associations with CRC, such as Met 1 composed of fatty acids, ceramides, and lysophospholipids, which is negatively associated with CRC, and Met 2 composed of phosphatidylcholine species, nucleosides, and amino acids, which is strongly associated with CRC.
Article
Hematology
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A. Johnson, Neha Mehta-Shah, Julie Lisano, Rachael Wen, Alev Akyol, Alison J. Moskowitz
Summary: The combination therapy of nivolumab and brentuximab vedotin showed long-term efficacy in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL), suggesting potential clinical applications.
Meeting Abstract
Oncology
M. Kloft, W. Allum, D. Cunningham, R. Langley, M. Nankivell, D. Magee, H. Grabsch
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Nalinie Joharatnam-Hogan, Duaa Hatem, Fay H. Cafferty, Giovanna Petrucci, David A. Cameron, Alistair Ring, Howard G. Kynaston, Duncan C. Gilbert, Richard H. Wilson, Richard A. Hubner, Daniel E. B. Swinson, Siobhan Cleary, Alex Robbins, Mairead MacKenzie, Martin W. G. Scott-Brown, Sharmila Sothi, Lesley K. Dawson, Lisa M. Capaldi, Mark Churn, David Cunningham, Vincent Khoo, Anne C. Armstrong, Nicola L. Ainsworth, Gail Horan, Duncan A. Wheatley, Russell Mullen, Fiona J. Lofts, Axel Walther, Rebecca A. Herbertson, John D. Eaton, Ann O'Callaghan, Andrew Eichholz, Mohammed M. Kagzi, Daniel M. Patterson, Krishna Narahari, Jennifer Bradbury, Zuzana Stokes, Azhar J. Rizvi, Georgina A. Walker, Victoria L. Kunene, Narayanan Srihari, Aleksandra Gentry-Maharaj, Angela Meade, Carlo Patrono, Bianca Rocca, Ruth E. Langley
Summary: Ongoing clinical trials are assessing whether aspirin can prevent or delay metastases in cancer patients. It was found that platelet activation levels in post-surgery cancer patients are associated with tumor type, recent treatment, and aspirin use. The study suggests that aspirin, especially at a dose of 100 mg, may help inhibit platelet activation and potentially prevent cancer metastasis.
BRITISH JOURNAL OF CANCER
(2023)
Editorial Material
Oncology
Ian Chau
Meeting Abstract
Oncology
Neil McCafferty, Caroline Fong, Louise J. Barber, Andrew Woolston, Dimitrios Kleftogiannis, Taqia Rana, Susan Cromarty, Shannon Kidd, Ruwaida Begum, Ian Chau, Naureen Starling, David Cunningham, Marco Gerlinger
Meeting Abstract
Oncology
Marco Gerlinger, Anderley Gordon, Louise J. Barber, Georgios Laliotis, Avani Athauda, Benjamin Challoner, Andrew Woolston, Sonia Mansukhani, Matt Dunstan, Nikoletta Petrou, Komel Khabra, Retchel Lazaro-Alcausi, Richard Crux, Victoria Borja, Ruwaida Begum, Isma Rana, Charuta Palsuledesai, Meenakshi Malhotra, Minetta Liu, Adham Jurdi, Shruti Sharma, Sheela Rao, Sacheen Kumar, David Cunningham, Ian Chau, Naureen Starling, M. Asif Chaudry
Article
Oncology
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell, Clare Peckitt, Caroline Fong, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Fribbens, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham, Nicola Valeri
Summary: This study identified miR-148a-3p as a potential biomarker for trastuzumab-based therapy in HER2-positive oesophago-gastric cancer patients. The results showed that the expression level of miR-148a-3p is associated with patient survival and progression rates.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)